Evidence map›Paper›PMID 22785048›Full record

ArticleThe Pediatric infectious disease journal2012

Use of a high resolution melting assay to analyze HIV diversity in HIV-infected Ugandan children.

Maria M James, Lei Wang, Deborah Donnell, Matthew M Cousins, Linda Barlow-Mosha, Jessica M Fogel, William I Towler, Allison L Agwu, Danstan Bagenda, Micheal Mubiru and 2 more

Open access · greenAbstract read
In one paragraph

Article in The Pediatric infectious disease journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Maria M JamesDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Lei Wang
Deborah Donnell
Matthew M Cousins
Linda Barlow-Mosha
Jessica M Fogel
William I Towler
Allison L Agwu
Danstan Bagenda
Micheal Mubiru
Philippa Musoke
Susan H Eshleman
Johns Hopkins University · USCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZAMUJHU Research Collaboration · UGInfectious Disease Research Institute · US

Funding

SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) GroupU01AI068632 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI JACKSON, J BROOKS · 2006 to 2010
$109.7M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
HIV Prevention Trials Network: Network LaboratoryU01AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ESHLEMAN, SUSAN H · 2006 to 2010
$16.5M
Laboratory and Statistical Development of Cross-Sectional HIV Incidence AssaysR01AI095068 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ESHLEMAN, SUSAN H · 2011 to 2021
$6.6M
Impact of maternal HAART on HIV-infected breastfeeding infants: MalawiR01AI087139 · NIAID · JOHNS HOPKINS UNIVERSITY · PI ESHLEMAN, SUSAN H · 2010 to 2013
$2.4M
NIAID NIH HHS 1R01-AI095068NIAID NIH HHS R01 AI087139NIAID NIH HHS R01 AI095068NIAID NIH HHS U01 AI068613NIAID NIH HHS U01-AI068613NIAID NIH HHS U01 AI068632NIAID NIH HHS U01-AI068632NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1-AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1-AI068617
6 · The paper itself

Abstract

backgroundWe used a novel high resolution melting (HRM) diversity assay to analyze HIV diversity in Ugandan children (age 0.6-12.4 years) who were enrolled in an observational study of antiretroviral treatment (ART). Children were maintained on ART if they were clinically and immunologically stable.

methodsHIV diversity was measured before ART (baseline) in 76 children and after 48 or 96 weeks of ART in 14 children who were not virally suppressed. HIV diversity (expressed as HRM scores) was measured in 6 regions of the HIV genome (2 in gag, 1 in pol, 3 in env).

resultsHigher baseline HRM scores were significantly associated with older age (≥2 years, P ≤ 0.001 for all 6 regions). HRM scores from different regions were weakly correlated. Higher baseline HRM scores in 3 regions (1 in gag, 2 in env) were associated with ART failure. HIV diversity was lower in 4 regions (2 in gag, 1 in pol, 1 in env) after 48-96 weeks of nonsuppressive ART compared with baseline.

conclusionsHigher levels of HIV diversity were observed in older children before ART, and higher levels of diversity in some regions of the HIV genome were associated with ART failure. Prolonged exposure to nonsuppressive ART was associated with a significant decrease in viral diversity in selected regions of the HIV genome.

Indexed as

Genetic VariationAgingAnti-HIV AgentsCD4 Lymphocyte CountChildChild, PreschoolCohort StudiesHIVHIV InfectionsHumansInfantUgandaViral LoadAnti-HIV Agents

Identifiers

PMID22785048
PMCPMC3473149
OpenAlexW2002103344

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.